Trade RYTM anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Rhythm Pharmaceuticals, Inc. (RYTM) is trading at US$102.67, down 2.12% today as of Sep 4, 12:41 EDT. The company has a market capitalisation of US$7.57B. Over the past 52 weeks, RYTM has traded between US$74.50 and US$122.20. On Syfe you can trade RYTM with $0 commission and add it to your watchlist.
| Previous close | US$104.89 |
|---|---|
| Market cap | US$7.57B |
| 52-week range | US$74.50 – US$122.20 |
| Volume | 269.77K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Year: 2017
RBC Adjusts Price Target on Rhythm Pharmaceuticals to $155 From $141, Maintains Outperform Rating
Aug 5, 12:48 PM · MT Newswires
Rhythm Pharmaceuticals, Inc. (RYTM) stock is trading at US$102.67, -2.12% from the previous close of US$104.89.
The market cap for Rhythm Pharmaceuticals, Inc. (RYTM) stock is approximately US$7.57B.
The 52-week high for Rhythm Pharmaceuticals, Inc. (RYTM) stock is US$122.20.
The 52-week low for Rhythm Pharmaceuticals, Inc. (RYTM) stock is US$74.50.
Rhythm Pharmaceuticals, Inc. (RYTM) does not currently pay a dividend.
Stay on top of RYTM
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
